Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136029 · ClinicalTrials.gov registry record · Early Phase 1
Exercise and NO in HFrEF
A Early Phase 1 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 68
- Enrollment target
NCT03136029: Completed Early Phase 1 study, sponsored by VA Office of Research and Development.
NCT03136029 is a Early Phase 1 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03136029, a Early Phase 1 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
Heart disease is the leading cause of death in the United States, accounting for one in every four deaths in 2010 and costing over $300 billion annually in health care, medication, and lost productivity. Heart failure with a reduced ejection fraction (HFrEF), a clinical syndrome that develops as a consequence of heart disease, now affects almost 6 million Americans. Within the VA Health Care System, HFrEF hospital admission rates continue to rise, and remain the number one reason for discharge from VA hospitals nationwide. Unfortunately, over one-third of all Veterans suffering from HFrEF die within two years of discharge despite optimized drug therapy, an unacceptably high number. This proposal is focused on how impaired muscle blood flow contributes to exercise intolerance in HFrEF, and on subsequently developing strategies for restoring exercise tolerance and slowing disease progression in this patient group. It is anticipated that knowledge gained from these studies will contribute to improved standard of care, quality of life, and prognosis in this VA patient group.
Interventions
- OTHER Exercise training
- DIETARY_SUPPLEMENT Antioxidant
- DIETARY_SUPPLEMENT Tetrahydrobiopterin (BH4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2025-07-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03136029
The ClinicalTrials.gov registry entry for NCT03136029 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Exercise training is the first listed.
NCT03136029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03136029 about?
NCT03136029 is a clinical study titled "Exercise and NO in HFrEF". Heart disease is the leading cause of death in the United States, accounting for one in every four deaths in 2010 and costing over $300 billion annually in health care, medication, and lost productivity. Heart failure with a reduced ejection fraction (HFrEF), a clinical syndrome that develops as a c...
What is the current status of trial NCT03136029?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 68 participants. The study started on 2018-06-01. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT03136029?
The interventions under investigation include: Exercise training (OTHER), Antioxidant (DIETARY_SUPPLEMENT), Tetrahydrobiopterin (BH4) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03136029?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.